HitGen(SH:688222)2024-01-19 09:52Company Overview - Chengdu XianDao Pharmaceutical Development Co., Ltd. aims to become a world-class innovative biopharmaceutical company focused on small molecule and nucleic acid drug discovery and optimization [3][4] - The company has developed a DNA-encoded compound library (DEL) technology, with over 1.2 trillion molecules in its library, covering more than 6,000 types of synthetic scaffolds [4][5] - Established in 2012, the company has subsidiaries in Cambridge, UK, and Houston, USA, and operates globally across North America, Europe, Asia, Africa, and Oceania [4][5] Technology and Innovation - The DEL technology is a core competency, with a high screening success rate of approximately 80%, surpassing the industry average for high-throughput screening (HTS) [7] - The company has published nearly 20 academic papers related to DEL technology and has received multiple awards for its innovative compounds [6][7] - Chengdu XianDao has developed a series of targeted applications, such as "DEL For Protein Degradation" and "DEL For GPCRs," to meet specific client needs [7][8] Drug Development Platforms - The company has established a comprehensive platform for oligonucleotide drug development, covering design, synthesis, and delivery systems [12][13] - A subsidiary, Sichuan XianDong Pharmaceutical Co., Ltd., has launched a GMP production facility for oligonucleotides, capable of meeting clinical trial demands [13][14] - The company is advancing its pipeline with two lead candidates targeting ANGPTL4 and AGT, expected to enter clinical trials in 2024 [14] Competitive Advantages - Chengdu XianDao is recognized as a leader in DEL technology development in China, with a diverse compound library and mature screening techniques [5][6] - The company has established partnerships with major pharmaceutical companies, including Pfizer and Johnson & Johnson, enhancing its market position [5][6] - The DEL screening approach is tailored for protein-protein interaction (PPI) targets, providing a robust tool for drug discovery [15][16] Future Outlook - The company emphasizes the long-term nature of innovative drug development and encourages rational investment from stakeholders [17] - Ongoing optimization of the second-generation IL-17A small molecule product pipeline is a key focus area [17]